The clinical studies included in this section attest to both the safety and effectiveness of Silybin Phytosome, the active ingredient in Maximum Milk Thistle™ and UltraThistle®.
The reason these studies were originally conducted was to have Silybin Phytosome introduced as a pharmaceutical drug in Europe. Unlike here in the U.S., European doctors take botanical medicine very seriously. Physicians prescribe herbal preparations on a regular basis for specific conditions and diseases.
(Ref20C15) Effect of Silybin Phytosome on chronic active hepatitis:
Study shows significant reduction in elevated liver enzymes (and therefore hepatocellular necrosis) in just one week of treatment with Silybin Phytosome.
(Ref21C13) Therapeutic effect of Silybin Phytosome in chronic liver disease:
A small study of eight human subjects with chronic active hepatitis. This study shows significant benefits of Silybin Phytosome after just two months treatment.
(Ref8P22) Direct comparison of Silybin Phytosome to standardized milk thistle extract:
Study shows nearly 10x the bioavailability of Silybin Phytosome over the world’s best selling standardized extract.
(Ref18C14) Useful dosages of Silybin Phytosome:
Shows definite advantages of Silybin Phytosome at dosages ranging from 160mg to 360mg (measured as silybin). Dose/effect relationship is also demonstrated with the highest dosage tested getting the most dramatic results.
(c10) Considerably greater bioavailability of silybin as a component of Silybin Phytosome:
Laboratory study shows that binding silybin with phosphatidylcholine on a molecular level dramatically improves its bioavailablity on a cellular level.
(c3medline) Increased oral bioavailability of Silybin Phytosome in humans:
Human study compares Silybin Phytosome and the worlds best selling standardized milk thistle extract and shows how much better the results are with Silybin Phytosome.
(Ref9C8) Effect of Silybin Phytosome on cirrhotic patients:
Study shows that Silybin Phytosome does not significantly differ in its safe and beneficial activity in patients with cirrhosis vs. healthy control subjects.
(Ref12P19) Liver damage control properties of Silybin Phytosome:
Silybin Phytosome shows significant protective activity against liver damage. This study tested Silybin Phytosome protection against a variety of toxins.
(Ref13P6) Free radical scavenging properties of Silybin Phytosome:
Study shows the capability of Silybin Phytosome to scavenge free radicals and inhibit lipid peroxidation. It also demonstrates significantly higher blood plasma levels of silybin when administered as a component of Silybin Phytosome rather than in its unbound form.
(Ref14P13) Effect of silimarin on lipid peroxidation:
Study shows milk thistle extract (silymarin) to be a helpful antioxidant and silybin to be the most valuable constituent of silymarin.
(Ref15P16) Silybin Phytosome counteracts hepatotoxic effects:
Study shows Silybin Phytosome protects liver cells against free-radical mediated toxic liver injury.
(Ref16P23) Antioxidant activity of Silybin Phytosome against alcohol:
Study shows how Silybin Phytosome is dramatically more effective than pure silybin alone. Concludes Silybin Phytosome may be useful in counteracting damage caused by alcohol intake.
(Ref19C6) Tolerablility and effectiveness of Silybin Phytosome:
Study shows high dose tolerability of Silybin Phytosome as well as its increased effectiveness over conventional standardized milk thistle extract.
(c6medline) Liver protection potential of Silybin Phytosome:
Study shows the antioxidant and free radical scavenging effect of Silybin Phytosome.
(Ref7P12) Comparative bioavailability of Silybin Phytosome vs. silybin:
Study shows exactly how much better silybin is absorbed when combined on a molecular level with phosphatidylcholine (a patented process resulting in Silybin Phytosome).
(Ref11P1) Liver protective activity:
Shows Silybin Phytosome is more effective than its constituents, silybin and phosphatidylcholine, alone. The effectiveness of Silybin Phytosome is considerably greater than the sum of its parts.
Shows silymarin compounds likely decrease serum transaminases in patients with chronic viral hepatitis, but do not appear to affect viral load or liver histology.
- Clinical Studies
- Clinical Study – Ref20C15
- Clinical Study – Ref21C13
- Clinical Study – Ref8P22
- Clinical Study – Ref18C14
- Clinical Study – C10
- Clinical Study – C3Medline
- Clinical Study – Ref9C8
- Clinical Study – Ref12P19
- Clinical Study – Ref13P6
- Clinical Study – Ref14P13
- Clinical Study – Ref15P16
- Clinical Study – Ref16P23
- Clinical Study – Ref19C6
- Clinical Study – C6Medline
- Clinical Study – Ref7P12
- Clinical Study – Ref11P1